Thinking about what to do with GMO Payment Gateway stock? You're not alone. With the company's shares closing most recently at 8,484 yen, many investors are trying to read the tea leaves and figure out whether this is a hidden gem or a stock best left on the sidelines. Over the past week, the price is up a modest 2.0%, suggesting some renewed optimism, but it's worth noting that the one-year return sits at -2.7% and the stock is still down 15.7% over five years. That longer-term underperformance stands out during a period when the broader payment technology sector has seen plenty of buzz and competitive shakeups.
Much of this recent action comes as market participants continue to weigh changing consumer payment habits and evolving regulations in Japan's fintech landscape. These shifts have sometimes made investors more cautious about risk. GMO Payment Gateway's shares have not quite bounced back like some global peers. Measured through a set of valuation checks, the company earns a value score of just 1 out of 6, meaning it is only considered undervalued in a single area right now.
So, what does this all mean for you? Next, I'll break down the main valuation approaches and how GMO Payment Gateway stacks up. And later in the article, I'll share a smarter way to spot value that investors often overlook.
GMO Payment Gateway scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown .
Approach 1: GMO Payment Gateway Excess Returns Analysis
The Excess Returns valuation model looks at whether a company is generating profits above what it costs to fund its operations, based on shareholders' equity. This approach judges how efficiently GMO Payment Gateway is turning invested capital into bottom-line earnings, using forward-looking estimates of its core profitability and book value per share.
For GMO Payment Gateway, analysts estimate a stable Earnings Per Share (EPS) of ¥369.67, sourced from future return on equity projections by eight analysts. The company's average return on equity is a robust 20.27%, which is notably strong for the diversified financial sector. The cost of equity, which refers to what investors require in return for their capital, totals ¥102.23 per share. The company's current book value per share stands at ¥1,440.04, and the stable book value is projected at ¥1,823.29, based on future estimates from seven analysts. This setup produces an excess return of ¥267.43 per share, the value generated above the cost of equity.
Based on these projections, the model estimates the intrinsic value of GMO Payment Gateway at ¥7,080 per share. With the current share price at ¥8,484, the stock appears 19.8% overvalued by this approach.
Result: OVERVALUED
Our Excess Returns analysis suggests GMO Payment Gateway may be overvalued by 19.8%. Find undervalued stocks or create your own screener to find better value opportunities.
Approach 2: GMO Payment Gateway Price vs Earnings
The Price-to-Earnings (PE) ratio is a classic and effective way to value profitable companies, as it reflects how much investors are willing to pay for each unit of earnings. For businesses with positive and reasonably stable profits such as GMO Payment Gateway, PE offers a straightforward gauge that reflects investor sentiment and expectations for future growth.
A company's "normal" or "fair" PE ratio will depend on its growth prospects, risk profile, and how it compares to the wider industry or market. Higher expected growth or lower risk typically justify a higher PE, while declining earnings or elevated risk push the fair value down. At present, GMO Payment Gateway trades at a PE of 32.1x. This sits just below the peer average of 35.2x, but well above the Diversified Financial industry average of 13.1x, signaling that the market sees GMO as faster-growing or less risky than many sector competitors.
This is where the Simply Wall St "Fair Ratio" comes in. The Fair Ratio, calculated specifically for the company, reflects a preferred multiple that accounts for GMO Payment Gateway's unique mix of earnings growth, industry conditions, profit margins, size, and risk factors. This approach goes beyond simple peer or sector comparisons and is designed to capture a more accurate sense of what the market should pay. For GMO Payment Gateway, the Fair Ratio is 19.9x, which is noticeably below the current PE of 32.1x. This suggests that, even after factoring in higher growth or profitability, the stock is trading above what fundamentals would support.
Result: OVERVALUED
PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth .
Upgrade Your Decision Making: Choose your GMO Payment Gateway Narrative
Earlier we mentioned that there is an even better way to understand valuation, so let's introduce you to Narratives. A Narrative is your investment story, a way to connect your view of GMO Payment Gateway's potential with your own numbers for future revenue, earnings, and profit margins. Think of Narratives as a bridge that links the company's story to real-world financial forecasts and a personal sense of what fair value should be.
Narratives are an easy yet powerful tool you can access right on Simply Wall St's Community page, used by millions of investors worldwide. They let you quickly compare your own Fair Value estimate to the current share price, so you can see at a glance if you think the stock is a buy or a wait. Narratives also update automatically as new earnings, news, and insights emerge, so your analysis always reflects the latest data.
For example, some investors on the platform see GMO Payment Gateway's fair value above ¥9,000 due to growth optimism, while others estimate it below ¥7,000 due to industry risks. Narratives help you make investment decisions that genuinely fit your outlook, not just the market's.
Do you think there's more to the story for GMO Payment Gateway? Create your own Narrative to let the Community know!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 3769 .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
